The celiac ganglion modulates LH-induced inhibition of androstenedione release in late pregnant rat ovaries.

Publisher: BioMed Central Country of Publication: England NLM ID: 101153627 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7827 (Electronic) Linking ISSN: 14777827 NLM ISO Abbreviation: Reprod Biol Endocrinol Subsets: MEDLINE

Original Publication: London : BioMed Central, 2003-

Androstenedione/*metabolism ; Ganglia, Sympathetic/*drug effects ; Ganglia, Sympathetic/*physiology ; Luteinizing Hormone/*pharmacology ; Ovary/*drug effects ; Ovary/*metabolism; Animals ; Female ; Norepinephrine/pharmacology ; Pregnancy ; Rats ; Rats, Sprague-Dawley ; Time Factors

Background: Although the control of ovarian production of steroid hormones is mainly of endocrine nature, there is increasing evidence that the nervous system also influences ovarian steroidogenic output. The purpose of this work was to study whether the celiac ganglion modulates, via the superior ovarian nerve, the anti-steroidogenic effect of LH in the rat ovary. Using mid- and late-pregnant rats, we set up to study: 1) the influence of the noradrenergic stimulation of the celiac ganglion on the ovarian production of the luteotropic hormone androstenedione; 2) the modulatory effect of noradrenaline at the celiac ganglion on the anti-steroidogenic effect of LH in the ovary; and 3) the involvement of catecholaminergic neurotransmitters released in the ovary upon the combination of noradrenergic stimulation of the celiac ganglion and LH treatment of the ovary.
Methods: The ex vivo celiac ganglion-superior ovarian nerve-ovary integrated system was used. This model allows studying in vitro how direct neural connections from the celiac ganglion regulate ovarian steroidogenic output. The system was incubated in buffer solution with the ganglion and the ovary located in different compartments and linked by the superior ovarian nerve. Three experiments were designed with the addition of: 1) noradrenaline in the ganglion compartment; 2) LH in the ovarian compartment; and 3) noradrenaline and LH in the ganglion and ovarian compartments, respectively. Rats of 15, 19, 20 and 21 days of pregnancy were used, and, as an end point, the concentration of the luteotropic hormone androstenedione was measured in the ovarian compartment by RIA at various times of incubation. For some of the experimental paradigms the concentration of various catecholamines (dihydroxyphenylalanine, dopamine, noradrenaline and adrenaline) was also measured in the ovarian compartment by HPLC.
Results: The most relevant result concerning the action of noradrenaline in the celiac ganglion was found on day 21 of pregnancy resulting in the inhibition of androstenedione release from the ovarian compartment. In addition on day 15 of pregnancy, LH placed in the ovarian compartment led to an inhibition of the release of androstenedione, and this inhibitory effect was further reinforced by the joint action of noradrenaline in the celiac ganglion and LH in the ovary. The levels of catecholamines in the ovarian compartment showed differences among the experiments; of significance, the joint treatment of noradrenaline in the celiac ganglion and LH in the ovary resulted in a remarkable increase in the ovarian levels of noradrenaline and adrenaline when compared to the effect achieved by either one of the compounds added alone.
Conclusion: Our results demonstrate that the noradrenergic stimulation of the celiac ganglion reinforces the LH-induced inhibition of androstenedione production by the ovary of late pregnant rats, and that this effect is associated with marked changes in the release of catecholamines in the ovary.

J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):385-93. (PMID: 8541235)
Biol Reprod. 1999 Mar;60(3):729-32. (PMID: 10026123)
Brain Res. 1999 Mar 6;821(1):141-9. (PMID: 10064798)
Steroids. 1999 Sep;64(9):618-23. (PMID: 10503718)
Med Sci Monit. 2004 Dec;10(12):BR440-6. (PMID: 15567974)
J Neuroendocrinol. 2005 Dec;17(12):846-58. (PMID: 16280032)
Endocrine. 2005 Dec;28(3):319-24. (PMID: 16388122)
Reproduction. 2006 Feb;131(2):361-8. (PMID: 16452729)
Reproduction. 2006 Jun;131(6):1151-8. (PMID: 16735554)
Biol Reprod. 2000 Oct;63(4):1000-5. (PMID: 10993820)
J Endocrinol. 2000 Aug;166(2):307-18. (PMID: 10927620)
J Endocrinol. 2001 Sep;170(3):575-84. (PMID: 11524237)
Biol Reprod. 2001 Oct;65(4):1114-9. (PMID: 11566732)
Cell Tissue Res. 2001 Nov;306(2):231-7. (PMID: 11702234)
Biol Reprod. 2002 May;66(5):1540-7. (PMID: 11967221)
Microsc Res Tech. 2002 Dec 15;59(6):462-73. (PMID: 12467021)
Microsc Res Tech. 2002 Dec 15;59(6):484-9. (PMID: 12467023)
Microsc Res Tech. 2002 Dec 15;59(6):495-502. (PMID: 12467025)
Biol Reprod. 2003 Jun;68(6):2222-31. (PMID: 12606359)
J Steroid Biochem Mol Biol. 2004 Jul;91(3):139-45. (PMID: 15276621)
J Reprod Dev. 2004 Aug;50(4):411-7. (PMID: 15329472)
Endocrinology. 1980 Jul;107(1):280-8. (PMID: 6247138)
Anat Rec. 1980 Jan;196(1):51-9. (PMID: 7416501)
Neuroscience. 1983 May;9(1):191-211. (PMID: 6192355)
Endocr Rev. 1985 Summer;6(3):371-99. (PMID: 3896767)
Clin Chem. 1986 Nov;32(11):2030-3. (PMID: 3096593)
Neurosci Lett. 1988 Feb 29;85(2):217-22. (PMID: 3374837)
J Electron Microsc Tech. 1989 Aug;12(4):408-16. (PMID: 2671307)
Brain Res. 1991 Feb 22;542(1):35-42. (PMID: 1675921)
Annu Rev Neurosci. 1993;16:471-507. (PMID: 8384808)
J Steroid Biochem Mol Biol. 1994 Nov;51(3-4):191-7. (PMID: 7981128)
Endocrinology. 1995 Dec;136(12):5760-8. (PMID: 7588334)
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11819-23. (PMID: 8524856)
J Comp Physiol B. 1995;165(6):464-70. (PMID: 8576456)
Neurosci Lett. 1996 Feb 16;205(1):65-7. (PMID: 8867022)
J Endocrinol. 1998 Feb;156(2):253-9. (PMID: 9518870)

409J2J96VR (Androstenedione)
9002-67-9 (Luteinizing Hormone)
X4W3ENH1CV (Norepinephrine)

Date Created: 20061223 Date Completed: 20070301 Latest Revision: 20181201

20250114

PMC1769501

10.1186/1477-7827-4-66

17184551